|
Precancerous Conditions
|
0.010 |
Biomarker
|
group |
BEFREE |
Thus, we identified three miRNAs (hsa-miR-421, hsa-miR-29b-1-5p, and hsa-miR-27b-5p) with two mRNAs (FBXO11 and CREBZF) that might play an important role in the GC development from premalignant adenomas.
|
29725252 |
2018 |
|
Cancerophobia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Smartphone problem-solving and behavioural activation therapy to reduce fear of recurrence among patients with breast cancer (SMartphone Intervention to LEssen fear of cancer recurrence: SMILE project): protocol for a randomised controlled trial.
|
30413519 |
2018 |
|
Severe myopia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Forty-three eyes with high myopia and thin corneas were enrolled.All eyes underwent SMILE procedure.
|
28963702 |
2018 |
|
Dryness of eye
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
A new type of corneal refractive surgery, SMILE, which has less impact on corneal nerves, induces less postoperative dry eye, supporting the association between corneal denervation and postoperative dry eye.
|
30481814 |
2018 |
|
Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Smartphone problem-solving and behavioural activation therapy to reduce fear of recurrence among patients with breast cancer (SMartphone Intervention to LEssen fear of cancer recurrence: SMILE project): protocol for a randomised controlled trial.
|
30413519 |
2018 |
|
Stomach Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, we identified three miRNAs (hsa-miR-421, hsa-miR-29b-1-5p, and hsa-miR-27b-5p) with two mRNAs (FBXO11 and CREBZF) that might play an important role in the GC development from premalignant adenomas.
|
29725252 |
2018 |
|
Lymphoma, Extranodal NK-T-Cell
|
0.010 |
Biomarker
|
disease |
BEFREE |
SMILE (steroid, methotrexate, ifosfamide, L-asparaginase, and etoposide) or other L-asparaginase-containing therapy is promising for advanced-stage ENKL, followed by either autologous or allogeneic hematopoietic stem cell transplantation.
|
29368155 |
2018 |
|
Myopic astigmatism
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A retrospective case series was conducted at Eye subspecialty center, Cairo, Egypt on 9 eyes with myopia or myopic astigmatism (spherical equivalent - 8.0 and - 12.0D). undergoing SMILE procedure and needed second interference.
|
29454328 |
2018 |
|
Steatohepatitis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Hepatic CREBZF couples insulin to lipogenesis by inhibiting insig activity and contributes to hepatic steatosis in diet-induced insulin-resistant mice.
|
29637572 |
2018 |
|
Fatty Liver Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
These findings uncover an unexpected mechanism that couples changes in extracellular hormonal signals to hepatic lipid homeostasis; disrupting CREBZF function may have the therapeutic potential for treating fatty liver disease and insulin resistance.(Hepatology 2018).
|
29637572 |
2018 |
|
Myopia
|
0.030 |
Biomarker
|
disease |
BEFREE |
Comparative study of wave-front aberration and corneal Asphericity after SMILE and LASEK for myopia: a short and long term study.
|
30894159 |
2019 |
|
Nasal Type Extranodal NK/T-Cell Lymphoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
<b>Conclusion</b>: Our analysis confirms that SMILE regimen, which is current standard to treat advanced-stage ENKTL may be associated with more severe hematological toxicity compared to other L-asparaginase combinations, including methotrexate-based (AspaMetDex, MESA and MEDA) or gemcitabine-based (GELOX, PGEMOX, DDGP, GDL, GOLD, GLIDE) or CCRT-based regimens.
|
30449214 |
2019 |
|
Heart failure
|
0.020 |
Biomarker
|
disease |
BEFREE |
The present subgroup analysis from the post-marketing surveillance SMILE Study aims to explore the efficacy and safety of tolvaptan across the HF subgroups (HFrEF, HFpEF, and HFmrEF).Patients with HF accompanied by fluid retention who received tolvaptan were enrolled.
|
31484861 |
2019 |
|
Congestive heart failure
|
0.020 |
Biomarker
|
disease |
BEFREE |
The present subgroup analysis from the post-marketing surveillance SMILE Study aims to explore the efficacy and safety of tolvaptan across the HF subgroups (HFrEF, HFpEF, and HFmrEF).Patients with HF accompanied by fluid retention who received tolvaptan were enrolled.
|
31484861 |
2019 |
|
Astigmatism
|
0.010 |
Biomarker
|
disease |
BEFREE |
Clinical outcomes and vector analysis of astigmatism were reviewed and compared between wavefront-guided laser in situ keratomileusis (LASIK) (WFG group) (STAR S4 IR with iDesign aberrometer; Johnson & Johnson Vision Care, Inc., Santa Ana, CA), topography-guided LASIK (TOPO group) (Allegretto Wave Eye-Q laser; Alcon Laboratories, Inc., Fort Worth, TX), and small incision lenticule extraction (SMILE group) (VisuMax laser; Carl Zeiss Meditec AG, Jena, Germany).
|
31710370 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Factors associated with improvement in symptoms and quality of life for first-line EGFR-tyrosine kinase inhibitor treatment in patients with <i>EGFR</i>-mutated non-small-cell lung cancer - A multicenter prospective SMILE study.
|
31417660 |
2019 |
|
ovarian neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
Targeting HDAC4, HIF-1α and CREBZF may be considered in treatment of ovarian cancer with p53 and RAS mutations.
|
30867818 |
2019 |
|
Malignant neoplasm of ovary
|
0.010 |
Biomarker
|
disease |
BEFREE |
Targeting HDAC4, HIF-1α and CREBZF may be considered in treatment of ovarian cancer with p53 and RAS mutations.
|
30867818 |
2019 |
|
Liver regeneration disorder
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
In contrast, adeno-associated virus mediated overexpression of CREBZF in the liver inhibits the expression of cyclin gene family and attenuates liver regeneration in CCl<sub>4</sub> -treated mice.
|
31469186 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.010 |
Biomarker
|
disease |
BEFREE |
Targeting HDAC4, HIF-1α and CREBZF may be considered in treatment of ovarian cancer with p53 and RAS mutations.
|
30867818 |
2019 |
|
Myopia
|
0.030 |
Biomarker
|
disease |
BEFREE |
In this single-center case series, lenticules were obtained from patients undergoing SMILE for the correction of myopia and the lenticule patch graft was performed in three patients with limbal dermoid.
|
31735992 |
2020 |
|
Dermoid Cyst
|
0.010 |
Biomarker
|
disease |
BEFREE |
To report a novel technique to treat superficial limbal dermoid by using the corneal intrastromal lenticules obtained from SMILE and to evaluate the initial clinical outcomes of lenticule patch graft for treatment of limbal dermoid.
|
31735992 |
2020 |